BioXcel Therapeutics Submits sNDA for At-Home Use of IGALMI® in Agitation Treatment

summarizeResumen

BioXcel Therapeutics' submission of a supplemental New Drug Application (sNDA) for IGALMI® to include at-home use is a very important development. This expansion targets a significant unmet medical need, as there are currently no FDA-approved options for the acute treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting. If approved, this could substantially broaden the addressable market for IGALMI®, driving significant revenue growth for the company and potentially transforming its commercial outlook.

check_boxEventos clave

• sNDA Submission for IGALMI®

  BioXcel Therapeutics announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IGALMI® on January 14, 2026.

• Expanded At-Home Use Indication

  The sNDA seeks to expand IGALMI's label to include at-home use for the acute treatment of agitation associated with bipolar disorders or schizophrenia, addressing a market with no currently FDA-approved options.

• Existing FDA Approval

  IGALMI® was previously approved by the FDA in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider.

auto_awesomeAnalisis

BioXcel Therapeutics' submission of a supplemental New Drug Application (sNDA) for IGALMI® to include at-home use is a very important development. This expansion targets a significant unmet medical need, as there are currently no FDA-approved options for the acute treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting. If approved, this could substantially broaden the addressable market for IGALMI®, driving significant revenue growth for the company and potentially transforming its commercial outlook.